Our approach to Parkinson's disease care avoids the harmful drug carbidopa. Please review the following information, which discusses the harmful effects of the drugs used in traditional Parkinson's care approaches.

CDC data:

1958-1975 the Parkinson’s disease death rate decreased1976-present the Parkinson’s death rate increased by 390%

WARNINGS --- LODOSYN (Carbidopa) has no antiparkinsonian effect

Our Position

We are not claiming that we have published a study definitively showing carbidopa caused the 328.7% increase in the Parkinson’ death rate between 1976 and 2011. We have published a hypothesis to serve as a starting point to study this problem. Consider the following example:

The Facts:

89% of Parkinson’s disease patients take a combination pill containing carbidopa. This approach does not use carbidopa.

The Bottom Line:

• Carbidopa depletes vitamin B6, when on an optimal diet this represent B6 relative nutritional deficiency• Vitamin B6 depletion causes an increased death rate• The next question for the study is, “Does carbidopa increase the death rate?”

Figure 1 - Center for Disease Control data: Between 1958 and 1975 there was no carbidopa, only L-dopa was available. The Parkinson’s death rate dropped.

Figure 2 - Center for Disease Control Data: As published in the carbidopa B6 death paper, between 1976 (the first full year of carbidopa sales) and 2011, the Parkinson’s death rate increased by 328.7%. Currently, between 1976 and 2014 (the most recent CDC data point) the Parkinson’s death rate has increased by 390%.

The first step in solving a problem is defining what the problem might be.

A hypothesis is a starting point for scientific studies. The carbidopa B6 death paper documents the purposed hypothesis, it reads:

The hypothesis: “Systemic vitamin B6 concentrations inversely correlate with mortality induced by coronary artery disease, colorectal cancer, stroke, heart failure, and atherosclerosis. We hypothesize that if carbidopa and benserazide significantly deplete PLP (vitamin B6), then an increased death rate will be observed.”

The paragraph goes on to note: “During the first 15 years of prescribing L-dopa (1960–1975) it was administered without carbidopa, a practice that was associated with a decreasing death rate. On May 9, 1975, the US FDA approved carbidopa for concomitant administration with L-dopa. Between 1976 and 2011, there has been an increase in the general Parkinson’s disease death rate.”

Other Carbidopa Depletions, Consider The Following:

Carbidopa is known to induced niacin deficiency (vitamin B3). The enzyme which metabolizes tryptophan to niacin is a B6 enzyme.

Depletion of vitamin B6 is known to occur with carbidopa and Parkinson’s disease. These are two of the 29 causes of relative nutritional deficiency that can occur in Parkinson’s disease patients while taking carbidopa with L-dopa.

Histamine synthesis is dependant on two vitamin B6 enzymes. Carbidopa induced vitamin B6 depletion can induce antihistamine dyskinesias which respond to stopping carbidopa then administering adequate amounts of vitamin B6, something that needs to be done under the care of a licensed caregiver properly trained in this approach. We have proven this in our clinics. We have cared for many patients successfully who were thought to have permanent; irreversible dyskinesias caused by L-dopa when in fact the cause was carbidopa induced B6 depletion.

Click below to read our dyskinesia paper posted on the National Institute of Health website.

Perspective, Our Position

As memorialized in the carbidopa B6 death paper: “It is illogical to assert that an increased carbidopa-induced death rate will not occur under these circumstances. In an attempt to control a benign condition (nausea – caused by the improperly balanced administration of a nutrient, L-dopa), the patient has been exposed to the devastating consequences of these drugs. While a formidable number of studies may still be needed to define all of the PLP (B6) depletion ramifications, they become unnecessary in the effective management of Parkinson’s disease when the nutrient protocol is implemented, since carbidopa and benserazide are no longer indicated.”

- Alvin Stein, MD

Establishing Validity

The proper approach for expressing disagreement with a formal scientific paper is writing a formal peer-reviewed rebuttal, in this case to the National Institute of Health standards. There has been no formal scientific challenge to this paper. Those with interests in protecting these drugs at all cost, independent of the facts, have posted smoke and mirror internet opinions that are not formal scientific writings. We are aware of the embellishment of second-hand facts not related to the science discussed on this webpage that has brought people reading them to anger. Everyone, take a deep breath. These are important observations which need attention. Our papers meet the National Institute of Health (NIH) standard for classification as peer-reviewed scientific medical papers. No one person wrote the six Parkinson’s disease papers. For these papers to be published required, seven medical doctor authors, eighteen medical doctor peer-reviewers and two editors-in-chief, twenty-seven highly skilled and highly trained people had to approve of the contents before publication.

For more information on our approach to Parkinson’s disease send an email to info@parkinsonsclinics.com or call 218-626-2220. After you send your email, we may ask for more information. All communications will be kept confidential. If you have any questions, please call us free of charge.

Contact information

For more information on how we can help care for your symptoms of PD, please contact us today.

Elsewhere

The purpose of this website is to share information on the medical services we offer to prospective patients.

DISCLAIMER: Parkinson’s Clinics refers those in medical need to licensed medical doctors. We also provide worldwide consultation to licensed healthcare providers. This approach does not use prescription drugs to address your condition.